ZAPLETALOVÁ, Danica, Nicolas ANDRE, Ladislav DEAK, Michal KÝR, Viera BAJČIOVÁ, Peter MÚDRY, Lenka DUBSKÁ, Regina DEMLOVÁ, Zdeněk PAVELKA, Karel ZITTERBART, Jarmila SKOTÁKOVÁ, Karel HUŠEK, Alexandra MARTINČEKOVÁ, Pavel MAZÁNEK, Tomáš KEPÁK, Michael DOUBEK, Lucia KÚTNIKOVÁ, Dalibor VALÍK and Jaroslav ŠTĚRBA. Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience. Oncology. Basel: S. Karger AG, 2012, vol. 82, No 5, p. 249-260. ISSN 0030-2414. Available from: https://dx.doi.org/10.1159/000336483.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience
Authors ZAPLETALOVÁ, Danica (703 Slovakia, belonging to the institution), Nicolas ANDRE (250 France), Ladislav DEAK (703 Slovakia), Michal KÝR (203 Czech Republic, belonging to the institution), Viera BAJČIOVÁ (703 Slovakia, belonging to the institution), Peter MÚDRY (203 Czech Republic, belonging to the institution), Lenka DUBSKÁ (203 Czech Republic, belonging to the institution), Regina DEMLOVÁ (203 Czech Republic, belonging to the institution), Zdeněk PAVELKA (203 Czech Republic, belonging to the institution), Karel ZITTERBART (203 Czech Republic, belonging to the institution), Jarmila SKOTÁKOVÁ (203 Czech Republic, belonging to the institution), Karel HUŠEK (203 Czech Republic, belonging to the institution), Alexandra MARTINČEKOVÁ (203 Czech Republic, belonging to the institution), Pavel MAZÁNEK (203 Czech Republic, belonging to the institution), Tomáš KEPÁK (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Lucia KÚTNIKOVÁ (703 Slovakia, belonging to the institution), Dalibor VALÍK (203 Czech Republic) and Jaroslav ŠTĚRBA (203 Czech Republic, guarantor, belonging to the institution).
Edition Oncology, Basel, S. Karger AG, 2012, 0030-2414.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.165
RIV identification code RIV/00216224:14110/12:00060447
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1159/000336483
UT WoS 000303655300001
Keywords in English Children; Solid tumor; Tumor angiogenesis; Metronomic chemotherapy; Relapsed pediatric solid tumor
Tags International impact
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 22/4/2013 18:36.
Abstract
The outcome of children with refractory/relapsed malignancies remains poor and novel therapies are urgently required. One of the promising approaches is metronomic chemotherapy. We present the clinical results of 74 children with advanced solid tumors treated according to treatment recommendation with data registry in three European pediatric centers. COMBAT (Combined Oral Metronomic Biodifferentiating Antiangiogenic Treatment) included low-dose daily temozolomide, etoposide, celecoxib, vitamin D, fenofibrate and retinoic acid. From 2004 to 2010, 74 children were enrolled. The 2-year overall survival (OS) was 43.1% (median 15.4, range 1.3-69.9 months). Of the 74 patients, 50 patients (68%) died and 24 are alive: 6 (8%) with progressive disease, 7 (9%) with stable disease/partial response and 11 (15%) in complete response. Median time to response was 6 months. Of 62 patients with initially measurable disease, 25 (40%) had radiological response or stable disease. Fourteen of 25 showing clinical benefit responded within the first 6 months. The treatment was well tolerated on an outpatient basis. Regarding non-hematological toxicity of grade >= 2, hepatotoxicity of grade 3 occurred in 8 children and grade 3 cheilitis in 16 children. COMBAT is a feasible and effective treatment option for patients with relapsing/refractory malignancies. The treatment is well tolerated with a low acute toxicity profile.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
MUNI/A/0950/2010, interní kód MUName: Metronomická léčba v dětské onkologii
Investor: Masaryk University, Category A
PrintDisplayed: 14/6/2024 14:11